Parkinson’s Disease News and Research RSS Feed - Parkinson’s Disease News and Research

β-amyloid deposition highly variable in synucleinopathy

β-amyloid deposition highly variable in synucleinopathy

A meta-analysis suggests large variability in the prevalence of β-amyloid deposition in patients with synucleinopathies. [More]
RBD persists in Parkinson’s disease patients

RBD persists in Parkinson’s disease patients

Symptoms of rapid eye movement sleep behaviour disorder (RBD) are unlikely to resolve in patients with Parkinson’s disease, show the findings of a 3-year study. [More]
Olfactory bulb changes fall short as imaging marker for PD

Olfactory bulb changes fall short as imaging marker for PD

Functional and histopathological changes in the olfactory bulb in patients with Parkinson’s disease do not equate to a volume change that is detectable on magnetic resonance imaging, say researchers. [More]
Phase–amplitude coupling changes may underlie DBS success in parkinsonism

Phase–amplitude coupling changes may underlie DBS success in parkinsonism

Deep-brain stimulation of the subthalamic nucleus may improve motor symptoms in patients with Parkinson’s disease by reducing excessive cortical phase–amplitude coupling, researchers report in Nature Neuroscience. [More]
Impulse control disorders do not promote cognitive decline in PD

Impulse control disorders do not promote cognitive decline in PD

Impulse control disorders in patients with Parkinson’s disease are not associated with more marked impairment of cognitive function, researchers report. [More]
Early neuropsychiatric symptoms prevalent in PD

Early neuropsychiatric symptoms prevalent in PD

Neuropsychiatric symptoms, but not cognitive impairment, are common in early untreated patients with Parkinson’s disease, suggest findings from the multicentre Parkinson’s Progression Markers Initiative. [More]
Bilirubin levels raised in newly diagnosed Parkinson’s disease

Bilirubin levels raised in newly diagnosed Parkinson’s disease

Bilirubin levels are upregulated in patients with early Parkinson’s disease and are associated with disease progression at 2 years, a study shows. [More]
Deep brain stimulation reduces PD pain severity but does not prevent it

Deep brain stimulation reduces PD pain severity but does not prevent it

Subthalamic nucleus deep brain stimulation has a beneficial effect on pain severity in patients with Parkinson’s disease that persists for up to 8 years, say researchers, but new onset of musculoskeletal pain in many suggests its effects are not enduring. [More]
Discovery opens new drug development avenues for treating multiple diseases

Discovery opens new drug development avenues for treating multiple diseases

Researchers at the University of California, San Diego School of Medicine have discovered a control switch for the unfolded protein response (UPR), a cellular stress relief mechanism drawing major scientific interest because of its role in cancer, diabetes, inflammatory disorders and several neural degenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), otherwise known as Lou Gehrig's disease. [More]
Study: Blood test may help diagnose Fragile X syndrome related disorders in women

Study: Blood test may help diagnose Fragile X syndrome related disorders in women

A blood test may shed new light on Fragile X syndrome related disorders in women, according to a new study published in the March 25, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. Fragile X is the most common inherited form of intellectual disability and the most frequent genetic cause of autism. [More]
Mexican researcher close to finding a cure for Parkinson's disease

Mexican researcher close to finding a cure for Parkinson's disease

Parkinson's disease, which took world fame after being diagnosed in various personalities such as actor Michael J. Fox, the heavyweight champion Muhammad Ali and the painter Salvador Dalí, could be very close to a cure, thanks to a Mexican researcher which managed to eliminate its neurological effects with an immunosuppressant. [More]
Cumulative genetic risk may underlie many Parkinson’s cases

Cumulative genetic risk may underlie many Parkinson’s cases

Genetic risk for Parkinson’s disease may be due as much to multiple genes with small individual effects as to single high-risk genes, research suggests. [More]
TSRI scientists confirm ribosome assembly as new target for anti-cancer drugs

TSRI scientists confirm ribosome assembly as new target for anti-cancer drugs

Ribosomes, ancient molecular machines that produce proteins in cells, are required for cell growth in all organisms, accomplishing strikingly complex tasks with apparent ease. But defects in the assembly process and its regulation can lead to serious biological problems, including cancer. [More]
Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate disappoints in Parkinson’s disease

Creatine monohydrate fails to live up to its early promise in patients with Parkinson’s disease, show the results of the Long-term Study 1. [More]
Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Pharma Two B announced today that enrollment has been completed in the company's Phase IIb study of P2B001 for the treatment of early stage Parkinson's disease. One hundred and forty-nine patients enrolled in the study conducted at 29 clinical sites throughout the US and Israel. [More]
Perceived cost affects placebo response in Parkinson’s disease

Perceived cost affects placebo response in Parkinson’s disease

Patients with Parkinson’s disease may gain a greater benefit from a placebo treatment if they believe it to be expensive, research suggests. [More]
Patients with Parkinson's disease often face difficulties with reduced visual contrast acuity

Patients with Parkinson's disease often face difficulties with reduced visual contrast acuity

Patients with Parkinson's disease (PD) often have difficulties with visual acuity in low-contrast images. Because they may have normal high-contrast vision, this is often overlooked during routine eye exams. In the current issue of the Journal of Parkinson's Disease, researchers report that PD patients had significantly worse vision for low-contrast images at close (40 cm) and far (2 m) distances. Even for high-contrast images, PD patients' vision was deficient at far distances. [More]
UK scientists find new approach to treat Parkinson's disease

UK scientists find new approach to treat Parkinson's disease

UK scientists have developed a peptide that sticks to the protein that causes Parkinson's disease, stopping it from killing brain cells. The research highlights a potential new route for slowing the progress of this incurable disease. [More]
Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson’s disease, today announces the closing of a Series A financing of €8.7 million ($10 million) co-led by Sunstone Capital and Ysios Capital. [More]
Neurodegenerative disease research using NMR: an interview with Christian Griesinger

Neurodegenerative disease research using NMR: an interview with Christian Griesinger

Christian Griesinger, director of the NMR-based Structural Biology department at the Max-Planck Institute for Biophysical Chemistry, talks about his research into neurodegenerative diseases using NMR to examine the dynamics of disordered proteins. [More]
Advertisement
Advertisement